Lung Cancer News and Research

Latest Lung Cancer News and Research

ACT people live longer but may have more mental health issues: Report

Chief Health Officer Charles Guest's report on the health and wellbeing of the Australian Capital Territory (ACT) population between July 2006 and June 2008 was presented in the Legislative Assembly. It showed that life expectancy rate at birth in the ACT was 80.3 years for males and 84 for women. This was despite the fact that most are overweight and only a minority eats enough fruit and vegetables.

22 Sep 2010

Impact of cancer treatment on cardiovascular function

For the past two decades, cancer therapy has become more sophisticated and effective, resulting in an ever-expanding group of long-term cancer survivors. There is also a growing awareness of the potentially negative effects of cancer treatment on the heart and the management of cardiac disease during and after cancer therapy.

22 Sep 2010

Stanford Cancer Center announces successful treatment of 5,000th patient with CyberKnife system

When Lori Brownell's first tumor appeared − on her left carotid artery − it was surgically removed, leaving an inches-long incision to heal. It was eight years before the feeling returned to that side of her neck, and for a time, she couldn't drive because she couldn't turn her head far enough.

21 Sep 2010

Warning on Australian clinics offering safe alternatives to mammograms

Experts have warned that some private clinics that are offering safe alternatives to mammograms as breast cancer screening are doing more harm than good. It is seen that clinics offering services like botox, liposuction and spray tans are increasingly providing breast cancer screening that uses thermal imaging and “electrical impedance” technology. These methods are being used on women as young as 20, with claims they can detect cancer years earlier than mammograms.

20 Sep 2010

LCA receives Leadership in Advocacy Award

Lung Cancer Alliance received the Leadership in Advocacy Award at today's forum of the Congressional Black Caucus Health Braintrust in Washington D.C.

18 Sep 2010

Boehringer Ingelheim commences afatinib Phase III clinical trial in advanced breast cancer

Boehringer Ingelheim today announced the initiation of a phase III clinical trial to investigate one of its most advanced oncology pipeline compounds, afatinib, for the treatment of patients with advanced (metastatic) breast cancer. Afatinib is an oral compound (taken as a tablet), which is a next generation, targeted therapy, that irreversibly inhibits both, the epidermal growth factor receptor (EGFR/HER1) and the human epidermal receptor HER2, which are involved in tumour growth and spread.

18 Sep 2010

FDA decides to review information on Avastin for advanced HER2-negative breast cancer

Genentech, Inc., a member of the Roche Group, today announced that information submitted by the company to the U.S. Food and Drug Administration (FDA) during the review of the supplemental Biologics License Applications (sBLAs) for Avastin (bevacizumab) for previously untreated (first-line) advanced HER2-negative breast cancer has been deemed a major amendment.

18 Sep 2010

Accuray Incorporated showcases CyberKnife VSI System at ESTRO Annual Congress

Accuray Incorporated, a global leader in the field of radiosurgery, announced today that for the first time in Europe the company showcased its latest offering, the CyberKnife VSI System, at ESTRO 29, the Annual Congress of the European Society for Therapeutic Radiology and Oncology in Barcelona, Spain.

18 Sep 2010

Scott & White Healthcare recruits patients for Phase III lung cancer trial

Scott & White Healthcare in Round Rock, Texas is recruiting patients for a Phase III lung cancer trial aimed at preventing the disease's recurrence in previously treated patients. The trial will evaluate the potential of an immunotherapy called Antigen-Specific Cancer Immunotherapeutic (ASCI) for the treatment of Non-Small Cell Lung Cancer (NSCLC).

17 Sep 2010

Scientists discover new drug target to improve radiation effectiveness for treating cancer

Scientists at Washington University School of Medicine in St. Louis have discovered a new drug target that could improve the effectiveness of radiation for hard-to-treat cancers.

17 Sep 2010

Advocacy For Patients files free insurance appeals for consumers with chronic illness

Advocacy for Patients with Chronic Illness, Inc., one of the only organizations in America that files free insurance appeals for consumers with chronic illness nationwide - today filed comments with the United States Department of Health and Human Services, Department of Labor, and Internal Revenue Service both complimenting the Agencies for "the thoughtful approach taken by the Agencies in formulating these complex rules," and suggesting numerous improvements that should be made.

16 Sep 2010

Stanford Cancer Center to use TrueBeam radiation therapy technology for cancer patients

On Thursday, Sept. 16, the Stanford Cancer Center will become the first treatment center on the West Coast and the fifth in the world to offer cancer patients the TrueBeam, a machine that represents an exponential leap forward in the speed, power and precision of radiation therapy.

15 Sep 2010

microRNA 451 enhances treatment response in stomach cancer patients: Research

"The high presence of microRNA 451 enhances the response to treatment with chemo-radiotherapy and increases the survival of patients with stomach cancer", explained Dr. Jesús García-Foncillas, chief researcher of the Pharmacogenomics Laboratory at the Applied Medical Research Centre (CIMA) and Director of Oncology at the University Hospital of Navarra. This was one of the results presented at the IV Congress of the Spanish Society for Pharmacogenetics and Pharmacogenomic, recently held at CIMA.

15 Sep 2010

Researchers identify risk gene for schizophrenia

An international team of researchers has identified a risk gene for schizophrenia, including a potentially causative mutation, using genome-wide association data-mining techniques and independent replications.

15 Sep 2010

Molecule microRNA-21 enhances growth and survival of existing lung cancer

A tiny molecule that spurs the progression of non-small-cell lung cancer could become a player in fighting the disease, say researchers at UT Southwestern Medical Center, who published a study on how the molecule behaves in mice in the Sept. 14 issue of Cancer Cell.

14 Sep 2010

Biosystems International announces merger with MicroBioChips

Biosystems International (BSI), a biotechnology company specializing in the discovery of novel monoclonal antibody based diagnostics, announces its merger with the company MicroBioChips (MBC) by contribution of assets.

13 Sep 2010

Synta expands STA-9090 Phase 2 clinical trial in NSCLC

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that it was expanding its Phase 2 clinical trial of STA-9090 in patients with Stage IIIB and Stage IV non-small cell lung cancer (NSCLC) from up to 69 patients to up to 146 patients based on encouraging activity observed in the first stage of the two stage clinical trial.

13 Sep 2010

Cyclacel reaches SPA agreement with FDA for sapacitabine Phase 3 trial in AML

Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious diseases, today announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) regarding a Special Protocol Assessment (SPA) on the design of a pivotal Phase 3 trial for the Company's sapacitabine oral capsules as a front-line treatment in elderly patients aged 70 years or older with newly diagnosed acute myeloid leukemia (AML) who are not candidates for intensive induction chemotherapy.

13 Sep 2010

PCRI to host educational event on prostate cancer therapy

Dean Ornish MD, recognized for establishing the impact of diet on prostate cancer (and heart disease), along with over a dozen internationally recognized prostate cancer experts will meet with over 800 prostate cancer survivors and their significant others at the Los Angeles Marriott near LAX on September 11th and 12th to discuss the latest thinking on prostate cancer treatment.

13 Sep 2010

Three quarters of British adults support removal of shop displays of tobacco: Survey

Three quarters of British adults support the removal of shop displays of tobacco (73 per cent) and a complete ban on cigarette vending machines (77 per cent) according to a new survey commissioned by Cancer Research UK this weekend.

10 Sep 2010